-
51.发明申请公开(公告)号：US20220016209A1
公开(公告)日：2022-01-20
申请号：US17492219
申请日：2021-10-01
Applicant: Immatics Biotechnologies GmbH
Inventor： Jens FRITSCHE , Toni WEINSCHENK , Steffen WALTER , Peter LEWANDROWSKI , Harpreet SINGH
Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a WIC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
-
公开(公告)号：US20210369826A1
公开(公告)日：2021-12-02
申请号：US17390583
申请日：2021-07-30
Applicant: Immatics Biotechnologies GmbH
Inventor： Sabrina KUTTRUFF-COQUI , Toni WEINSCHENK , Jens FRITSCHE , Steffen WALTER , Norbert HILF , Oliver SCHOOR , Colette SONG , Harpreet SINGH
IPC: A61K39/00 , C07K14/47 , C07K14/705 , A61K35/17 , C07K7/06 , C07K7/08 , C07K14/74 , C07K16/28 , C12Q1/6886
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US20210253640A1
公开(公告)日：2021-08-19
申请号：US17238932
申请日：2021-04-23
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Toni WEINSCHENK , Steffen WALTER , Jens FRITSCHE , Colette SONG , Harpreet SINGH
Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
-
公开(公告)号：US20200031870A1
公开(公告)日：2020-01-30
申请号：US16599258
申请日：2019-10-11
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Toni WEINSCHENK , Steffen WALTER , Jens FRITSCHE , Colette SONG , Harpreet SINGH
Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
-
公开(公告)号：US20190321405A1
公开(公告)日：2019-10-24
申请号：US16507437
申请日：2019-07-10
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Toni WEINSCHENK , Oliver SCHOOR , Claudia TRAUTWEIN , Norbert HILF , Steffen WALTER , Harpreet SINGH
IPC: A61K35/17 , C07K7/06 , C12N9/10 , C07K14/47 , C07K14/495 , C12N9/02 , A61K39/00 , C07K7/08 , C07K14/725 , C07K16/40 , C12N5/0783 , C07K19/00
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
Patent Agency Ranking
公开(公告)号：US20190010190A1
公开(公告)日：2019-01-10
申请号：US16136008
申请日：2018-09-19
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Toni WEINSCHENK , Oliver SCHOOR , Claudia TRAUTWEIN , Norbert HILF , Steffen WALTER , Harpreet SINGH
IPC: C07K7/06 , A61K35/17 , C07K14/74 , A61K39/00 , C12N5/0783 , G01N33/574 , A61M5/00 , C07K7/08 , A61K38/00
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
57.发明申请公开(公告)号：US20170312336A1
公开(公告)日：2017-11-02
申请号：US15636958
申请日：2017-06-29
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Jens FRITSCHE , Toni WEINSCHENK , Steffen WALTER , Peter LEWANDROWSKI , Harpreet SINGH
CPC classification number: A61K38/1709 , A61K39/0011 , A61K2039/5158 , A61K2039/572 , A61K2039/585 , A61P35/00 , C07K7/06 , C07K2319/00 , G01N33/505
Abstract: A method of treating a patient who has gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has gastric cancer. A method of treating a patient who has gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the gastric cancer.
-
公开(公告)号：US20160376317A1
公开(公告)日：2016-12-29
申请号：US15226206
申请日：2016-08-02
Applicant: immatics biotechnologies GmbH
Inventor： Toni WEINSCHENK , Oliver SCHOOR , Claudia TRAUTWEIN , Norbert HILF , Steffen WALTER , Harpreet SINGH
IPC: C07K7/06 , A61M5/00 , C12N5/0783 , A61K39/00 , C07K14/74
CPC classification number: C07K7/06 , A61K35/17 , A61K38/00 , A61K39/0011 , A61K2039/5154 , A61K2039/5158 , A61K2039/53 , A61K2039/55511 , A61K2039/55516 , A61K2039/55522 , A61K2039/55561 , A61K2039/55588 , A61K2039/572 , A61K2039/605 , A61K2039/6081 , A61K2039/6093 , A61M5/002 , C07K7/08 , C07K14/70539 , C07K2319/00 , C07K2319/40 , C12N5/0638 , C12N2501/50 , G01N33/57492 , Y02A50/472
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US20160376312A1
公开(公告)日：2016-12-29
申请号：US15226038
申请日：2016-08-02
Applicant: immatics biotechnologies GmbH
Inventor： Toni WEINSCHENK , Oliver SCHOOR , Claudia TRAUTWEIN , Norbert HILF , Steffen WALTER , Harpreet SINGH
CPC classification number: C07K7/06 , A61K35/17 , A61K38/00 , A61K39/0011 , A61K2039/5154 , A61K2039/5158 , A61K2039/53 , A61K2039/55511 , A61K2039/55516 , A61K2039/55522 , A61K2039/55561 , A61K2039/55588 , A61K2039/572 , A61K2039/605 , A61K2039/6081 , A61K2039/6093 , A61M5/002 , C07K7/08 , C07K14/70539 , C07K2319/00 , C07K2319/40 , C12N5/0638 , C12N2501/50 , G01N33/57492 , Y02A50/472
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
公开(公告)号：US20230241111A1
公开(公告)日：2023-08-03
申请号：US18166936
申请日：2023-02-09
Applicant: Immatics Biotechnologies GmbH
Inventor： Toni WEINSCHENK , Oliver SCHOOR , Claudia TRAUTWEIN , Norbert HILF , Steffen WALTER , Harpreet SINGH
IPC: A61K35/17 , C07K7/06 , C07K7/08 , A61K39/00 , C07K14/47 , C07K14/495 , C07K14/725 , C07K16/40 , C07K19/00 , C12N9/02 , C12N9/10 , C12N5/0783
CPC classification number: A61K35/17 , C07K7/06 , C07K7/08 , A61K39/0011 , C07K14/47 , C07K14/495 , C07K14/7051 , C07K16/40 , C07K19/00 , C12N9/0036 , C12N9/13 , C07K14/4748 , C12N5/0638 , A61K38/00
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
-
-
-
-
-
-
-
-
-
Search Results
72
records
(took 0.04 seconds)
